Clinical trial · Observational
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
NCT02108457CI-TRIAL-00050948completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]Fluorothymidine (FLT) PET/CT Imaging | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Proton subjects
- interventionNames
- Radiation: [18F]Fluorothymidine (FLT) PET/CT Imaging
- label
- IMRT subjects
- interventionNames
- Radiation: [18F]Fluorothymidine (FLT) PET/CT Imaging
Primary outcomes (1)
- measure
- Patients With Changes in Bone Marrow Assessed Through Images
- timeFrame
- up to 5 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants will be 18 years of age or older * History of gynecologic cancer. * Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy * Female participants of child-bearing potential must have a negative urine or serum pregnancy test at the time of the screening visit. * Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific procedures. * Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician. Exclusion Criteria * Females who are pregnant or breast feeding at the time of screening will not be eligible for this study. * Inability to tolerate imaging procedures in the opinion of the investigator or treating physician * Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subjects safety or successful participation in the study. * Unwilling or unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.